tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Chordia Therapeutics Reports Fiscal Year 2025 Financial Results

Story Highlights
  • Chordia Therapeutics operates in the pharmaceutical industry, listed on the Tokyo Stock Exchange.
  • The company reported improved losses but decreased assets, indicating financial challenges.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Chordia Therapeutics Reports Fiscal Year 2025 Financial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Chordia Therapeutics Inc. ( (JP:190A) ).

Chordia Therapeutics Inc. reported its financial results for the fiscal year ending August 31, 2025, showing a slight improvement in losses compared to the previous year. The company’s total assets and net assets decreased significantly, indicating potential challenges in financial stability and operational efficiency.

More about Chordia Therapeutics Inc.

Chordia Therapeutics Inc. is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. It focuses on developing therapeutic solutions, although specific products or market focus details are not provided in the release.

Average Trading Volume: 852,988

Technical Sentiment Signal: Sell

Current Market Cap: Yen8.38B

Find detailed analytics on 190A stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1